Clinical trials: Schizophrenia Spectrum Disorders
Schizophrenia
Add-On Therapy to Risperidonein Schizophrenia
These results suggest that the DA neuroprotection provided by DM in the inflammation-related neurodegenerative models is not mediated through the NMDA receptor.
- Trial name
- DM (NCT01189006)
- Testing
- Dextromethorphan
- Where
- Taiwan
- Volunteers
- 161 people
- Sponsor
- National Cheng-Kung University Hospital
Schizophrenia, Schizoaffective Disorder
Comparing Mobile Health (mHealth) and Clinic-Based Self-Management Interventions for Serious Mental Illness
The study is a three year research project whose aims are to evaluate the willingness of individuals with serious mental illness to initiate the two illness self-management interventions- WRAP or FOCUS, to examine and compare…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT02421965
- Testing
- FOCUS (Smartphone Application), WRAP (Wellness Recovery Action Planning)
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Psychotic Disorders
A Patient-Centered Approach to Improve Screening for Side Effects of Second Generation Antipsychotics (SGAs)
The purpose of this study is to determine if individuals with serious mental illnesses exposed to a patient-centered computerized tool versus printed educational materials have higher rates of screening for the metabolic side…
- Trial name
- NCT00677898
- Testing
- Patient-centered computerized tool, Written educational materials
- Where
- United States
- Volunteers
- 239 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia
A Study on Etiological Factors of Schizophrenia
This PPG entitled "A Study on Etiological Factors of Schizophrenia" (SEFOS) focuses on searching for the separate etiological factors under the understanding that schizophrenia is a complex disorder.
- Trial name
- NCT00155636
- Volunteers
- 1,056 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Patients Using Olanzapine, Quetiapine, Risperidone or Clozapine
No Guts No Glory Probiotics
The goal of this clinical trial is to learn if probiotics work to prevent or reduce metabolic side effects caused by antipsychotic medication in adults.
- Trial name
- NGNGP (NCT07606014)
- Testing
- Probiotic Formula
- Where
- 3 sites in Netherlands
- Volunteers
- 112 people
- Sponsor
- University Medical Center Groningen
COMT Gene Polymorphism
Pharmacogenetics of Cannabinoid Response
This study attempts to examine genetic influences on the effects of tetrahydrocannabinol (Δ9-THC), the active ingredient of marijuana, cannabis, "ganja", or "pot".
- Trial name
- NCT00678730
- Testing
- delta 9 tetrahydrocannabinol
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Yale University
Schizophrenia Therapeutics
Berberine Improving Cognitive Impairments in Schizophrenia
This study is a 12-week, randomized, blank-controlled, assessor-blinded trial. Eligible patients were randomized in a 1:1 ratio to receive either berberine hydrochloride or blank control as an add on to their stable antipsychotic…
- Trial name
- NCT07359209
- Testing
- Berberine
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Tianjin Anding Hospital
Psychiatric Diagnosis, Schizophrenia Disorders
The Key to Integrated Trauma Treatment in Psychosis Trial
Schizophrenia spectrum disorders (SSDs) have a significant trauma etiology: trauma has been reported in 65 - 80% in this patient group and have a negative impact on prognosis.
- Conditions
- Psychiatric Diagnosis, Schizophrenia Disorders, Psychological Trauma, Historical
- Trial name
- KIT (NCT06608706)
- Testing
- Eye Movement Desensitization and Reprocessing (EMDR) for psychosis
- Where
- 11 sites in Norway
- Volunteers
- 187 people
- Sponsor
- Haukeland University Hospital
Schizophrenia, Schizo Affective Disorder
Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)
To characterize the real-life clinical use of AOM in a hospitalized patient population with schizophrenia, schizoaffective disorder or BP1 requiring LAI therapy and evaluate its short-term effectiveness associated with its…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
- Trial name
- INITIATE (NCT04907279)
- Testing
- Aripiprazole Once-Monthly (AOM)
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Otsuka Canada Pharmaceutical Inc.
Schizophrenia
Accelerated DMN-Targeted cTBS to Modulate DMN Connectivity
The central hypothesis is this: DMN connectivity can be modulated with inhibitory cTBS when delivered on an accelerated treatment schedule.
- Trial name
- NCT07155096
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Schizophrenia
What the Nose Knows: Hedonic Capacity, Psychosocial Interventions and Outcomes in Schizophrenia
This project proposes to conduct the first study of the predictive utility of olfactory hedonic measurement for targeted psychosocial rehabilitation in schizophrenia.
- Trial name
- NCT05282186
- Testing
- Cognitive Enhancement Therapy, Social Skills Training
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- Beth Israel Deaconess Medical Center
Schizophrenia
Bifeprunox Extension to Extension Study in Patients With Schizophrenia
The purpose of this study is to provide access to bifeprunox for patients, who have completed previous studies with bifeprunox, and require continued treatment with bifeprunox, other treatment not being adequate.
- Trial name
- NCT00861497
- Testing
- Bifeprunox
- Where
- Italy
- Volunteers
- 11 people
- Sponsor
- H. Lundbeck A/S
Weight Gain, Sialorrhea
FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey
AZUR Pharma has received several reports from practicing psychiatrists prescribing FazaClo showing that FazaClo patients start losing body weight instead of keep gaining it, after being switched from other clozapine products or…
- Trial name
- FOCUS (NCT00683891)
- Testing
- FazaClo (clozapine, USP) ODT
- Where
- 2 sites in United States
- Sponsor
- Azur Pharma, Inc
Schizophrenia, Treatment Resistant Depression
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
This pilot open-label study examines the effects of a combination of dasatinib plus quercetin - two drugs that have known senolytics properties - on physiological aging in older individuals with depression or schizophrenia.
- Conditions
- Schizophrenia, Treatment Resistant Depression, Aging, Premature
- Trial name
- NCT05838560
- Testing
- Dasatinib, quercetin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Agitation, Schizophrenia
Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department
This is a single-arm pilot study to examine the impact of BXCL501 (sublingual film formulation of dexmedetomidine) administration on reducing the severity of undifferentiated acute agitation in patients presenting to the…
- Conditions
- Agitation, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- NCT05974527
- Testing
- Sublingual film containing dexmedetomidine (BXCL501)
- Sponsor
- Brigham and Women's Hospital
Schizophrenia
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia
This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.
- Trial name
- CONVOKE (NCT05838625)
- Testing
- CT-155, Digital Control
- Where
- 54 sites in United States
- Volunteers
- 464 people
- Sponsor
- Click Therapeutics, Inc.
Velo-cardio-facial Syndrome, Psychosis
Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome
This is an exploratory clinical investigation. The objectives of this study are to evaluate the safety, steady-state pharmacokinetics, and efficacy of metyrosine (Demser®) for the treatment of psychosis in patients with…
- Trial name
- NCT01127503
- Testing
- Metyrosine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Bausch Health Americas, Inc.
Schizophrenia, Schizoaffective Disorder
Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis
This study will assess the effectiveness of an experimental treatment intervention for adolescents and adults who have experienced their first episode of psychosis during the past two years.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder
- Trial name
- NCT01216891
- Testing
- Multi-element, team-oriented treatment
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Research Foundation for Mental Hygiene, Inc.
Schizophrenia
Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study
Double - Blind, Randomized, single centered study. The purpose of this study is to assess the feasibility of minocycline vs. placebo, added to atypical antipsychotic medications, for positive symptoms in adults suffering from…
- Trial name
- NCT01133080
- Testing
- Minocycline
- Where
- 2 sites in Israel
- Volunteers
- 50 people
- Sponsor
- Shalvata Mental Health Center
Schizophrenia
Galantamine for Cognitive Deficits in Schizophrenia
The purpose of this study is to determine the acute effects of the nicotinic receptor allosteric modulator galantamine (0, 4 and 8 mg) on neurocognitive function in schizophrenic smokers (n=20) versus schizophrenic nonsmokers…
- Trial name
- NCT00463879
- Testing
- Galantamine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Yale University